Talis Biomedical Corporation. The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Northern District of California on behalf of shareholders of Talis Biomedical Corporation who purchased common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 2021 initial public offering.
According to the lawsuit, documents that the Company issued in connection with its IPO failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis’s Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company’s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
“Talis Biomedical Corporation”
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until March 8, 2022 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
To receive more information, please fill out the form.
